Abstract
Objective We examined trajectories of stress, depression, and cannabis use across the prenatal period. We also investigated whether individuals who reported using cannabis to alleviate stress and depressive symptoms experienced symptom relief across the prenatal period.
Methods Pregnant individuals (n=436) with a history of lifetime cannabis use were recruited and identified either as prenatal cannabis users (PCU; continued cannabis use following knowledge of pregnancy in the first trimester) or non-prenatal cannabis users (NPCU; no cannabis use following knowledge of pregnancy in the first trimester). PCU individuals additionally reported on reasons for continued cannabis use during pregnancy. We employed longitudinal multivariate modeling to examine trajectories of depression (maternal self-report; Edinburgh Postnatal Depression Scale), stress (maternal self-report; Perceived Stress Scale), and cannabis use (maternal self-report and urinalysis) over time, stratified by motives for use during the perinatal period.
Results Stress, depression, and cannabis use decreased from the first to the third trimester (slope B= -0.21, -0.35, and -0.31, respectively). While cannabis use and depression at the first trimester were correlated with one another, they did not affect the other’s rate of change. Cannabis use similarly did not affect the rate of change in stress. Finally, while individuals using cannabis to cope with mental health symptoms experienced a decrease in overall depression symptoms, this slope was roughly equivalent to individuals who were not using cannabis prenatally (slope B= - 0.43 and -0.51, respectively).
Conclusion Our sample experienced a collective decrease in depression, stress, and cannabis use prenatally. This decline in cannabis use – even among those who reported using to cope with mental health conditions – was not attributable to the decrease in depressive symptoms. This study lends valuable insight into the reasons why individuals continue to use cannabis during pregnancy, which providers can use to help tailor recommendations for other sources of coping and support to childbearing individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by DA046224
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Washington University in St. Louis School of Medicine name gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
